Lemtrada

 

Topic mentions per year

Topic mentions per year

2011-2015
01220112015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
  • Prescrire international
  • 2015
As of late 2014, interferon beta injection was the standard "disease-modifying" treatment for patients with relapsing-remitting… (More)
Is this relevant?
Review
2015
Review
2015
  • 2015
NEW DRUG APPROVALS Blincyto for Rare Form of ALL The FDA has approved blinatumomab (Blincyto, Amgen) to treat patients with… (More)
Is this relevant?
2014
2014
BACKGROUND Multiple sclerosis (MS) is a common complex disorder, with new treatment options emerging each year. Social media is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2014
Review
2014
The lymphocyte depleting anti-CD52 monoclonal antibody alemtuzumab has been used in Cambridge, UK, as an experimental treatment… (More)
Is this relevant?
2013
2013
Although some treatments are now available for multiple sclerosis, better treatments are needed for people with aggressive… (More)
Is this relevant?
Review
2012
Review
2012
Two long-awaited multiple sclerosis (MS) drugs, Sanofi’s (Genzyme) alemtuzumab (Lemtrada) and Biogen Idec’s BG-12 (dimethyl… (More)
Is this relevant?
Review
2012
Review
2012
Two long-awaited multiple sclerosis (MS) drugs, Sanofi’s (Genzyme) alemtuzumab (Lemtrada) and Biogen Idec’s BG-12 (dimethyl… (More)
  • table 1
Is this relevant?
2012
2012
Two clinical trials published in The Lancet have shown that a monoclonal antibody used to treat leukaemia is also an effective… (More)
Is this relevant?
2011
2011
volume 29 number 4 april 2011 nature biotechnology “The ERT business is the key asset,” says Fernandez. “To have a longer term… (More)
Is this relevant?
2011
2011
On March 7, the board of directors of Genzyme recommended that shareholders accept a buyout offer from global pharma giant Sanofi… (More)
  • table 1
Is this relevant?